Search
Acetrizoic acid
go.drugbank.com/drugs/DB09347ApprovedWithdrawn[A32135] It was first synthesized by Wallingford in 1953[A32136] and it was filled in the FDA by the Johnson & Johnson subsidiary, Cilag Chemie AG, on February 8th, 1978. … Acetrizoic acid presents the molecular formula of 3-acetamidol-2,4,6-triiodobenzoic acid[L1702] and it is the first monomeric ionic compound used as an X-ray contrast agent.
Enlicitide
go.drugbank.com/drugs/DB22580ApprovedInvestigationalAcross two 52-week placebo-controlled trials, enlicitide 20 mg once daily reduced LDL-C at Week 24 by 56% relative to placebo in patients with hypercholesterolemia at established or increased ASCVD risk … (CORALreef Lipids), and by 59% in patients with HeFH (CORALreef HeFH), with comparable reductions in non-HDL-C and apolipoprotein B.
Safusidenib
go.drugbank.com/drugs/DB18745InvestigationalSynonyms: DS-1001 free acid, (2E)-3-[1-[[5-(1-Fluoro-1-methylethyl)-3-(2,4,6-trichlorophenyl)-4-isoxazolyl]carbonyl]-3-methyl-1H-indol-4-yl]-2-propenoic acidTechnetium Tc-99m tilmanocept
go.drugbank.com/drugs/DB09266ApprovedIt is a macromolecule consisting of multiple units of diethylenetriaminepentaacetic acid (DTPA) and mannose, each covalently attached to a 10 kDa dextran backbone [FDA Label]. … DTPA serves as a chelating agent for technetium Tc 99m to bind [FDA Label].
Angelica dahurica root
go.drugbank.com/drugs/DB14255InvestigationalAngelica dahurica root is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Synonyms: Bai ZhiChlorquinaldol
go.drugbank.com/drugs/DB13306Approved[F4549] It was marketed in the 1950s as an iodine-free alternative which was also unrelated to sulfa drugs or hormones. … Chlorquinaldol was used historically as a topical antiseptic under the trade name Sterosan.
Mixtures: IMPETEX %0.1 + %1 KREM, 10 G, NERISONA-C %0,1 + %1 KREM, 10 GRTalquetamab
go.drugbank.com/drugs/DB16678ApprovedInvestigationalTalquetamab is a IgG4-PAA bispecific G protein-coupled receptor class C group 5 member D (GPRC5D)-directed CD3 T-cell engager. … [L47775] Talquetamab was fully approved by the EMA on August 22, 2023.[L48822] On August 9, 2023, talquetamab was granted FDA accelerated approval.[L47770]
Synonyms: -CHAIN, (231->224'), (234->227')-BIS(DISULFIDE), IMMUNOGLOBULIN G4-KAPPA/G4-LAMBDA, ANTI-(HOMO SAPIENS GPRC5D (G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D)), AND ANTI-(HOMO SAPIENS CD3E (CD3 EPSILON, LEU-4)), HUMANIZED AND CHIMERIC MONOCLONALTivozanib
go.drugbank.com/drugs/DB11800ApprovedInvestigationalIt was approved on March 10, 2021 by the FDA. Marketed by Aveo Oncology, tivozanib is a promising therapy for individuals with RCC who have not been treated successfully with other therapies.[L32524] … Renal cell carcinoma (RCC) is responsible for 3% of cancer cases[A231314] and is one of the 10 most common cancers in adults. The average age of diagnosis is between age 65 to 74.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates